U.S. Government Accountability Office, 2015-06: GAO found per-beneficiary Part B drug spending, including oncology drugs, was substantially higher at 340B disproportionate-share hospitals than at non-340B hospitals in 2008 and 2012, and recommended Congress consider removing the incentive to prescribe more or pricier drugs there.
in 2012, average per beneficiary spending at 340B DSH hospitals was $144, compared to $60 and $62 at non-340B DSH and other non-340B hospitals, respectively.
p. 20
U.S. Government Accountability Office, 2015-06: GAO found per-beneficiary Part B drug spending, including oncology drugs, was substantially higher at 340B disproportionate-share hospitals than at non-340B hospitals in 2008 and 2012, and recommended Congress consider removing the incentive to prescribe more or pricier drugs there. Study type: regulatory record.
